By J. Jala | 11:28 PM March 04, 2021
The Governor Celestino Gallares Memorial Hospital (GCGMH) in Tagbilaran City will be allocated with 8,440 Sinovac’s CoronaVac Covid-19 vials from the 2nd batch of vaccines for Central Visayas.
The Silliman University Medical Center Foundation, Inc. in Dumaguete, Negros Oriental will have 1,200 vials.
A total of 9,640 doses of Sinovac vaccines for Central Visayas will be delivered tomorrow, March 5.
The Sinovac vaccines are set to arrive in Mactan Cebu International Airport from Manila at 7:40 AM. It will then be transported to Vicente Sotto Memorial Medical Center (VSMMC) Cold Room for sorting before the vaccines will be delivered to Bohol and Negros Oriental accordingly.
The Office of Civil Defense- Central Visayas (OCD-7) which is in-charge of the logistics has asked for OPAV’s assistance through their Assistant Regional Director Engr. Neil Balaba.
The Office of the Presidential Assistant for the Visayas (OPAV) then arranged for a vessel transport for both deliveries with the help of PNP Maritime Group-Regional Maritime Group 7 Chief PCol. Rizalino Padrique for Bohol, and of the Philippine Navy for Negros Oriental.
This development is seen to kick-off the mass inoculation in the provinces of Bohol and Negros Oriental.
Meanwhile, the vaccination program has already started in Cebu today, with its initial allocation of 7,200 vaccines. As of this writing, the vaccine rollout is ongoing at VSMMC.
The Duterte Administration gives prime to our health care workers, making them the top priority for vaccine jabs. For his part, Chair of the Senate Committee on Health Sen. Bong Go assures the public that they have nothing to fear as the vaccines are proven safe and effective. He urges government agencies to intensify the education drive in a whole-of-nation approach to boost vaccine confidence through a clear vaccination roadmap. President Duterte and Sen. Go are both ensuring the success of the vaccination program as the Philippines is geared towards economic recovery.
The efficacy of Sinovac against COVID-19 administered in two doses at two-week interval is 50.65% for all cases, 83.75% for cases requiring medical treatment, and 100% for hospitalized, severe and fatal cases, based on trials.